CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION

CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION

Author de Oliveira Dias, Joao Rafael Autor UNIFESP Google Scholar
de Andrade, Gabriel Costa Autor UNIFESP Google Scholar
Kniggendorf, Vinicius Ferreira Autor UNIFESP Google Scholar
Novais, Eduardo Amorim Autor UNIFESP Google Scholar
Maia, Andre Autor UNIFESP Google Scholar
Meyer, Carsten Autor UNIFESP Google Scholar
Watanabe, Sung Eun Song Autor UNIFESP Google Scholar
Farah, Michel Eid Autor UNIFESP Google Scholar
Rodrigues, Eduardo Buschele Autor UNIFESP Google Scholar
Abstract Purpose: To evaluate the 6-month safety and efficacy of ziv-aflibercept intravitreal injections for treating exudative age-related macular degeneration. Methods: Fifteen patients with unilateral exudative age-related macular degeneration were enrolled. The best-corrected visual acuity was measured and spectral domain optical coherence tomography was performed at baseline and monthly. Full-field electroretinography and multifocal electroretinography were obtained at baseline and 4, 13, and 26 weeks after the first injection. All patients received three monthly intravitreal injections of ziv-aflibercept (1.25 mg) followed by as-needed treatment. Results: Between baseline and 26 weeks, the mean logMAR best-corrected visual acuity improved (P = 0.00408) from 0.93 +/- 0.4 (20/200) to 0.82 +/- 0.5 (20/160) logarithm of the minimum angle of resolution, respectively

the central retinal thickness decreased significantly (P = 0.0007) from 490.3 +/- 155.1 microns to 327.9 +/- 101.5 microns

the mean total macular volume decreased significantly (P < 0.0001) from 9.51 +/- 1.36 mm(3) to 8.08 +/- 1.34 mm(3), and the a-wave implicit time increased, with no differences in the other full-field electroretinography parameters. The average multifocal electroretinography macular responses within the first central 15 degrees showed significantly (P < 0.05) increased P-1 amplitudes at 26 weeks. No systemic or ocular complications developed. Conclusion: Intravitreal ziv-aflibercept significantly improved the best-corrected visual acuity, multifocal electroretinography amplitudes, central retinal thickness, and total macular volume from baseline to 26 weeks. No retinal toxicity on full-field electroretinography or adverse events occurred during the follow-up period.
Keywords ziv-aflibercept
age-related macular degeneration
full-field electroretinography
multifocal electroretinography
Language English
Sponsor Fundação de Amparo a Pesquisa do Estado de São Paulo (São Paulo, Brazil)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (Brasilia, Brazil)
Pan-American Association of Ophthalmology/Pan-American Ophthalmological Foundation, Paul Kayser Global Award, Arlington, TX
Date 2017
Published in Retina-The Journal Of Retinal And Vitreous Diseases. Philadelphia, v. 37, n. 8, p. 1499-1507, 2017.
ISSN 0275-004X (Sherpa/Romeo, impact factor)
Publisher Lippincott Williams & Wilkins
Extent 1499-1507
Origin http://dx.doi.org/10.1097/IAE.0000000000001385
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000406108700010
URI http://repositorio.unifesp.br/handle/11600/51479

Show full item record




File

Name: WOS000406108700010.pdf
Size: 430.9Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account